Also the antioxidant activity according to ABTS. FRAP and CUPRAC was significantly highest
in methanol extract for non-ripe Murtilla (878.18 +/- 41.2, 486.92 +/- 23.3 and 1012.42 +/- 43.2 mu M TE/g, respectively). The amount of polyphenol compounds and their antioxidant activities of Murtilla berries are significantly higher than in other studied berries and are comparable with blueberries and raspberries, however, these indices in the Murtilla-like non-ripe berries were the following: 31.55 +/- 1.4 selleck screening library mg GAE/g for polyphenols; 5.22 +/- 03, 12.16 +/- 0.6 and 224 +/- 0.1 mg CE/g for flavonoids, tannins and flavanols; ABTS, FRAP and CUPRAC: 244.22 +/- 12.1, 81.32 +/- 3.9 and 203.83 +/- 9.3 mu M TE/g, respectively. The correlation between the polyphenol compounds and the antioxidant activities were relatively high. DPPH kinetic measurements were used to compare, distinguish and discriminate the antiradical activity among berry methanolic extracts by multivariate analysis. 3-D fluorescence was used as an additional tool for the characterization of the polyphenol extracts during various stages of ripening and different berries cultivars. The interaction between methanol polyphenol extracts of Murtilla-like and bovine serum albumin (BSA) showed that the new kind of berries has a strong ability, as other studied berries, to HDAC cancer quench the intrinsic fluorescence of BSA by forming complexes.
In conclusion, for the first time these berries
were analyzed and compared with widely consumed cultivars, using their polyphenols’ composition, antioxidant activities and fluorescence properties. The ability of Murtilla-like berries to quench the intrinsic fluorescence of BSA and relatively high content of polyphenol compounds can be used as a new source of antioxidants. (C) 2011 Elsevier Ltd. All rights reserved.”
“BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a complication of organ transplantation.
The risk of developing PTLD varies depending on a number of factors, including the organ transplanted and the degree of immunosuppression used.
METHODS: We report a retrospective analysis of 35 patients with PTLD treated at our center after lung transplantation. Of 705 patients who received allografts, this website 34 (4.8%) developed PTLD. One patient underwent transplantation elsewhere and was treated at our center.
RESULTS: PTLD involved the allograft in 49% of our patients and the gastrointestinal (GI) tract lumen in 23%. Histologically, 39% of tumors were monomorphic and 48% polymorphic. The time to presentation defined the location and histology of disease. Of 17 patients diagnosed within 11 months of transplantation, PTLD involved the allograft in 12 (71%) and the GI tract in 1 (p = 0.01). This “”early”" PTLD was 85% polymorphic (p = 0.006). Conversely, of the 18 patients diagnosed more than 11 months after transplant, the lung was involved in 5 (28%) and the GI tract in 7 (39%; p = 0.01).